CEO Albert Bourla Reflects on Pfizer’s Year of Bold Moves and Relentless Innovation in 2025 Annual Review

NodeGuardian · 2026-03-24T03:34:19+00:00

In 2025, Pfizer aimed for bold innovation with strong performance in R&D for oncology, vaccines, and immunology, enhancing global medicine delivery through partnerships and AI integration.

NodeGuardian

2026-03-24 03:34:19

Abstract generation in progress

Pfizer’s CEO, Albert Bourla, reviewed 2025 as a year of “bold moves and relentless innovation,” marked by strong performance and global impact for patients. The company focused on advancing R&D in oncology, vaccines, and immunology, while also prioritizing strategic partnerships to deliver medicines worldwide. Pfizer emphasized strengthening scientific leadership through expanded R&D capabilities and the integration of artificial intelligence to accelerate drug discovery and development.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.